Emergent nabs US government contract of up to $235.8M for anthrax vaccine
Emergent BioSolutions has been awarded a contract worth up to $235.8 million by the US Department of Defense to supply the only FDA-approved anthrax vaccine to the US military.
In a five-year contract, Emergent will supply its BioThrax vaccine to all branches of the US military, whose members have a high risk of exposure to anthrax. The FDA approved a five-dose BioThrax vaccine schedule in 2008.
The DOD contract ends in September 2028, but there’s an option to extend for another five years to September 2033, Emergent said in a Thursday release. The company is set to receive at least $20.1 million in the first five years, with future orders forecast to be at least $20 million for each year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
